Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 3/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27617510 | 0.83 | AKR1C3 (0.43) | AKR1C3AKR1C2PTGDR2PTGDR | |
| SCHEMBL3555128 | 0.81 | BAZ2B (0.49) | POLB | |
| SCHEMBL3559889 | 0.81 | GFER (0.44) | PTGDR2POLB | |
| SCHEMBL3558589 | 0.78 | MAPT (0.51) | AKR1C3AKR1C2POLB | |
| SCHEMBL3560996 | 0.78 | POLB (0.42) | PTGDR2POLBPTGDR | |
| SCHEMBL3557610 | 0.76 | POLB (0.66) | POLB | |
| SCHEMBL6420808 | 0.75 | NPC1 (0.35) | POLB | |
| SCHEMBL9231566 | 0.72 | PTGDR2 (0.44) | AKR1C3AKR1C2PTGDR2POLBPTGDR | |
| SCHEMBL7140395 | 0.71 | AKR1C3 (0.42) | AKR1C3AKR1C2PTGDR2PTGDR | |
| SCHEMBL3556523 | 0.71 | GAA (0.44) | PTGDR2POLBPTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567492-B1 | N-ARYLSULFONYL-3-AMINOALKOXYINDOLES | SUVEN LIFE SCIENCES LTD (IN) | 2013-05-22 | — | — | EP | disclosed |
| US-7718690-B2 | N-arylsulfonyl-3-aminoalkoxyindoles | RAMAKRISHNA VENKATA SATYA NIROGI | 2010-05-18 | — | — | US | disclosed |
| US-20090131507-A1 | N-arylsulfonyl-3-aminoalkoxyindoles | SUVEN LIFE SCIENCES LIMITED (IN) | 2009-05-21 | — | — | US | disclosed |
| EP-1567492-A2 | N-ARYLSULFONYL-3-AMINOALKOXYINDOLES | Suven Life Sciences Limited (IN) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004048328-A2 | N-ARYLSULFONYL-3-AMINOALKOXYINDOLES | SUVEN LIFE SCIENCES LIMITED (IN) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004048331-A1 | N-ARYLALKYL-3-AMINOALKOXYINDOLES AND THEIR USE AS 5-HT LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131507-A1 | N-arylsulfonyl-3-aminoalkoxyindoles | HTR3C, HTR3A, AANAT | AKR1C3 1540/4885AKR1C2 1900/4885PTGDR2 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.